公司新闻

2025年7月17日，宁波三生生物科技股份有限公司（简称“宁波三生生物”）与列日大学（A·范德普拉斯肯教授实验室）签署合作协议，共同研发针对鳗鱼疱疹病毒1型（AngHV-1）的有效疫苗。鳗鱼作为中国水产养殖业的重要品种，深受消费者青睐。然而该病毒正在中国福建、广东等主要鳗鱼养殖区传播，对鳗鱼产业构成重大威胁。研究表明，该病毒可导致高达60%的死亡率，给鳗鱼养殖行业带来巨大经济损失。为遏制疾病传播并保障高产养殖业的健康安全，亟需研发有效疫苗。宁波三生生物与列日大学科研团队携手响应市场需求，共同推进疫苗研发工作。安德普拉斯肯教授实验室的研究工作获得比利时韦尔生物研究所（项目编号WELBIO-CR-2022 A-14 12)及欧洲海洋与渔业基金（Eel4ever）的资助支持。 鳗鱼健康养殖工程是宁波三生生物预防和管理水产养殖病害战略的重要组成部分。

On July 17th, 2025, the Ningbo Sansheng BiotechnologyCo. Ltd （Sansheng）and the University of Liège (Laboratory of Prof. A. Vanderplasschen) signed an agreement to jointly develop an effective vaccine against Anguillid herpesvirus 1 (AngHV-1). Eel is one of the major aquaculture fish species in China and the eel is widely liked by consumers.  However, AngHV-1 is circulating and posing a high threat to this species. The virus was detected and reported in major eel production areas of China such as Fujian and Guangdong. It can cause mortalities up to 60%, leading to very high economic losses to this industry.

An effective vaccine is needed to curb the disease and provide health assurance for high productivity.  Ningbo Sansheng Biotechnology Co. Ltd and University of Liège scientific team have committed to join hands to answer the call and develop this vaccine. Researches activities of the laboratory of Prof. A. Vanderplasschen are supported by the Wel Research Institute (WELBIO-CR-2022 A-14 12) and the European Maritime and Fisheries Fund (Eel4ever) (Belgium).  

The eel safeguarding project is an important part to fullfill Sansheng’s strategy to guard against aquaculture diseases.